Outset Medical

OM · NASDAQ

$4.22+$0.42 (+11.05%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $3.80

OM analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 6 analysts

Average $7.82 (+85.3% upside)

Low: $6.06
Now: $4.22
High: $10.50

Upgrades and downgrades

The latest rating actions, newest first

OM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
BTIG	Feb 12, 2026	Maintains	Buy	$17.00 → $15.00	56%
Stifel	Jan 7, 2026	Maintains	Buy	$14.00 → $8.00	62%
BTIG	Dec 16, 2025	Maintains	Buy	$17.00	56%
Stifel	Nov 11, 2025	Maintains	Buy	$17.00 → $14.00	62%
RBC Capital	Nov 11, 2025	Maintains	Sector Perform	$22.00 → $17.00	49%
BTIG	Nov 11, 2025	Maintains	Buy	$39.00 → $17.00	56%

The case for and against

Updated Jun 2, 2026

Bull case

Outset Medical is a medical technology company with a unique and innovative Tablo Hemodialysis System that offers simpler and more convenient dialysis treatment, saving time and money for both providers and patients. The recently FDA cleared next-gen Tablo system, with both hardware and software enhancements and cybersecurity advantages, could amplify demand and help grow the company's Console pipeline. With strong recurring revenue, improving margins, and a broad and growing deal pipeline, Outset Medical has potential for future growth and a solid quarter for rebuilding credibility.

Bear case

Outset Medical is a medical technology company that sells the Tablo Hemodialysis System for use in acute, chronic, and home care settings. It has unique features that help hospitals save money and allow patients to spend less time undergoing dialysis, including the ability to turn tap water into dialysate in real time. While a majority of its revenue is recurring, the stock's potential for growth may be limited compared to other medical technology companies due to its niche market and competition from larger, more established companies with similar products.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.